Randomized Comparison of Oral P2Y12-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor: The ExcelsiorLOAD2 Trial

JACC: Cardiovascular Interventions

Volumn 10, Issue 2, 2017, Pages 121-129

  Hochholzer, Willibald ^a   Kleiner, Pascal ^a   Younas, Iris ^a   Valina, Christian M ^a   Löffelhardt, Nikolaus ^a   Amann, Michael ^a   Bömicke, Timo ^a   Ferenc, Miroslaw ^a   Hauschke, Dieter ^b   Trenk, Dietmar ^a   Neumann, Franz Josef ^a   Stratz, Christian ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

cangrelor; clopidogrel; percutaneous coronary intervention; platelet reactivity; prasugrel; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ADENOSINE; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG FATALITY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATURIA; HEMOPERICARDIUM; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY DISEASE; DEVICES; DIAGNOSTIC IMAGING; DRUG EFFECTS; DRUG SUBSTITUTION; GERMANY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; STENT; THROMBOCYTE; THROMBOCYTE AGGREGATION; TIME FACTOR; TREATMENT OUTCOME;

ADENOSINE; ADENOSINE MONOPHOSPHATE; ADMINISTRATION, ORAL; AGED; BLOOD PLATELETS; CORONARY DISEASE; DRUG SUBSTITUTION; FEMALE; GERMANY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85010203558     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.10.004     Document Type: Article

References (34)

1. 1 Hochholzer, W., Trenk, D., Bestehorn, H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006), 1742–1750.
2. 2 Tantry, U.S., Bonello, L., Aradi, D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62 (2013), 2261–2273.
3. 3 Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–e122.
4. 4 Windecker, S., Kolh, P., Alfonso, F., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 35 (2014), 2541–2619.
5. 5 Bhatt, D.L., Stone, G.W., Mahaffey, K.W., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368 (2013), 1303–1313.
6. 6 Hochholzer, W., Trenk, D., Frundi, D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005), 2560–2564.
7. 7 Ferreiro, J.L., Ueno, M., Angiolillo, D.J., Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 7 (2009), 1195–1201.
8. 8 Angiolillo, D.J., Schneider, D.J., Bhatt, D.L., et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 34 (2012), 44–55.
9. 9 Dovlatova, N.L., Jakubowski, J.A., Sugidachi, A., Heptinstall, S., The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 6 (2008), 1153–1159.
10. 10 Judge, H.M., Buckland, R.J., Jakubowski, J.A., Storey, R.F., Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y receptors in vitro. Platelets, 2015, 1–5.
11. 11 U.S. Label of Kengrexal (Cangrelor). Available at: https://chiesiusa.com/wp-content/uploads/kengreal-us-prescribing-information.pdf. Accessed October 29, 2016.
12. 12 Schneider, D.J., Agarwal, Z., Seecheran, N., Keating, F.K., Gogo, P., Pharmacodynamic effects during the transition between cangrelor and ticagrelor. J Am Coll Cardiol Intv 7 (2014), 435–442.
13. 13 Tuffal, G., Roy, S., Lavisse, M., et al. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 105 (2011), 696–705.
14. 14 Wallentin, L., Varenhorst, C., James, S., et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 (2008), 21–30.
15. 15 Steinhubl, S.R., Oh, J.J., Oestreich, J.H., Ferraris, S., Charnigo, R., Akers, W.S., Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121 (2008), 527–534.
16. 16 Schneider, D.J., Seecheran, N., Raza, S.S., Keating, F.K., Gogo, P., Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis 26 (2015), 42–48.
17. 17 Bhatt, D.L., Lincoff, A.M., Gibson, C.M., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361 (2009), 2330–2341.
18. 18 Farid, N.A., Smith, R.L., Gillespie, T.A., et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 35 (2007), 1096–1104.
19. 19 Farid, N.A., Kurihara, A., Wrighton, S.A., Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50 (2010), 126–142.
20. 20 Small, D.S., Li, Y.G., Ernest, C.S. 2nd, et al. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent. J Clin Pharmacol 51 (2011), 321–332.
21. 21 Rollini, F., Franchi, F., Angiolillo, D.J., Switching P2Y-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 13 (2016), 11–27.
22. 22 Gurbel, P.A., Bliden, K.P., Butler, K., et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121 (2010), 1188–1199.
23. 23 Sibbing, D., Braun, S., Morath, T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53 (2009), 849–856.
24. 24 Thygesen, K., Alpert, J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White, H.D., Third universal definition of myocardial infarction. Eur Heart J 33 (2012), 2551–2567.
25. 25 Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
26. 26 Hochholzer, W., Amann, M., Titov, A., et al. Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention: the ExcelsiorLOAD trial. J Am Coll Cardiol Intv 9 (2015), 219–227.
27. 27 Rollini, F., Franchi, F., Cho, J.R., et al. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J 37 (2016), 2722–2730.
28. 28 Schuhlen, H., Kastrati, A., Dirschinger, J., et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 98 (1998), 104–111.
29. 29 Bellemain-Appaix, A., O'Connor, S.A., Silvain, J., et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 308 (2012), 2507–2516.
30. 30 Mehran, R., Baber, U., Steg, P.G., et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 382 (2013), 1714–1722.
31. 31 Angiolillo, D.J., Curzen, N., Gurbel, P., et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 Study (Switching Anti Platelet-2). J Am Coll Cardiol 63 (2014), 1500–1509.
32. 32 Wiviott, S.D., Trenk, D., Frelinger, A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007), 2923–2932.
33. 33 Angiolillo, D.J., Saucedo, J.F., Deraad, R., et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56 (2010), 1017–1023.
34. 34 Franchi, F., Faz, G.T., Rollini, F., et al. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: results of the prospective, randomized SWAP-3 study. J Am Coll Cardiol Intv 9 (2016), 1089–1098.